Efficacy and safety of cagrilintide s.c. 2.4 mg in combination with semaglutide s.c. 2.4 mg (CagriSema s.c. 2.4 mg/2.4 mg) once-weekly in participants with overweight or obesity
Phase 3
Recruiting
- Conditions
- obesitas en overgewichtObesityoverweight
- Registration Number
- NL-OMON53435
- Lead Sponsor
- ovo Nordisk
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 100
Inclusion Criteria
- Male or female
- Age above or equal to 18 years at the time of signing informed consent
- BMI greater than or equal to 30.0 kg/m^2 or b) BMI greater than or equal to
27.0 kg/m^2 with the presence of at least one weight related comorbidity
including, but not limited to hypertension, dyslipidaemia, obstructive sleep
apnoea or cardiovascular disease
Exclusion Criteria
Glycaemia related:
-HbA1c greater than or equal to 6.5 % (48 mmol/mol) as measured by the central
laboratory at screening
-History of type 1 or type 2 diabetes mellitus
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>Relative change in body weight From baseline (week 0) to end of treatment (week<br /><br>68) %<br /><br>Achievement of >= 5% weight reduction From baseline (week 0) to end of treatment<br /><br>(week 68) </p><br>
- Secondary Outcome Measures
Name Time Method